Abstract: Methods for determining a signal quality index for bioinformation measurement are disclosed herein. The method can include detecting a light intensity when the transmitter module is in an off state. The method can include comparing the light intensity to a first threshold. The method can include decreasing the gain of the receiver module when the light intensity is greater than the first threshold. The method can include comparing the light intensity to a second threshold when the light intensity is less than the first threshold. The method can include decreasing the gain of the receiver module when the light intensity is greater than the second threshold. The method can include comparing the light intensity to a third threshold when the light intensity is less than the second threshold. The method can include increasing the gain of the receiver module when the light intensity is less than the third threshold.

Abstract: An interleaving driving method of light emitting diode array comprises: receiving image signal; converting the image signal into gray scale signals, the gray scale signals correspond to the plurality of light emitting channels, respectively, to execute multiple steps. The multiple steps include: generating a high gray scale data group and a low gray scale data group; when there is data in the high gray scale data group, drive the light emitting diode channel corresponding to the target gray scale signal during a first turn on time interval; when there is data in the low gray scale data group, drive the light emitting diode channel corresponding to the target gray scale signal during a second turn on time interval which does not overlap the first turn on time interval and a first gray scale signal and a second gray scale signal of the gray scale signals does not overlap each other.

Abstract: Interconnect structure packages (e.g., through silicon vias (TSV) packages, through interlayer via (TIV) packages) may be pre-manufactured as opposed to forming TIVs directly on a carrier substrate during a manufacturing process for a semiconductor die package at backend packaging facility. The interconnect structure packages may be placed onto a carrier substrate during manufacturing of a semiconductor device package, and a semiconductor die package may be placed on the carrier substrate adjacent to the interconnect structure packages. A molding compound layer may be formed around and in between the interconnect structure packages and the semiconductor die package.

Abstract: An integrated inductor is provided. The integrated inductor includes a first winding and a second winding, and has a first end, a second end, and a node. The first winding utilizes the first end and the node as two ends thereof and includes a first coil and a second coil, which do not overlap. The second winding utilizes the second end and the node as two ends thereof and includes a third coil and a fourth coil, which do not overlap. The first coil and the third coil have an overlapping area, and the second coil and the fourth coil have an overlapping area. The first coil is surrounded by the third coil, and the fourth coil is surrounded by the second coil.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: A motion-sensing floor mat, an assembly of such floor mats, and a monitoring system with such floor mats are provided; wherein the floor mat can be joined with another such floor mat and electrically connected to a monitoring device to form the monitoring system; the monitoring device stores a queue list and a topology matrix and uses a topological algorithm to store the identification tag of each such floor mat detected into the queue list in order, to gradually establish the topology matrix for the floor mats detected; and to thereby obtain the relative positions of the floor mats detected. When any of the floor mats is subjected to pressure (e.g., when someone falls on the floor mat accidentally) and generates a sensing signal, the monitoring device can pinpoint the position of that floor mat (i.e., the location of the fall) rapidly according to the topology matrix.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Abstract: An “Interactive Text Completion System” provides various techniques for presenting a user with personalized context-based multi-word text completion suggestions via a user interface. The multi-word text completion suggestions are updated in real-time as the user types and/or selects one or more words of the completion suggestions. The Interactive Text Completion System applies a language model in combination with a document context to generate the completion suggestions. In various implementations, the language model is generated from a store of prior documents created or edited by the user. As such, the language model is personalized to individual users based on prior documents of those users. However, any desired source or corpus of existing documents can be used to generate the language model. The resulting language model offers relatively long completion suggestions (e.g., phrases consisting of a sequence of multiple words) based on the current document context.

Abstract: A motion-sensing floor mat, an assembly of such floor mats, and a monitoring system with such floor mats are provided; wherein the floor mat can be joined with another such floor mat and electrically connected to a monitoring device to form the monitoring system; the monitoring device stores a queue list and a topology matrix and uses a topological algorithm to store the identification tag of each such floor mat detected into the queue list in order, to gradually establish the topology matrix for the floor mats detected; and to thereby obtain the relative positions of the floor mats detected. When any of the floor mats is subjected to pressure (e.g., when someone falls on the floor mat accidentally) and generates a sensing signal, the monitoring device can pinpoint the position of that floor mat (i.e., the location of the fall) rapidly according to the topology matrix.

Abstract: The present invention provides an activity-sensing ground pad for integrating with a monitoring apparatus to continuously monitor human activity in the home environment. The activity-sensing ground pad includes a modular base, a sensing layer arranged on the modular base, an insulating layer arranged on the sensing layer, and a conductive elastic layer formed to cover the insulating layer. Specifically, the modular base has a first assembling side with a plurality of first engagement portions thereon and a second assembling side opposite to the first assembling side with a plurality of second engagement portions thereon, wherein a first electrical connector is arranged on one of the engaging portions, and a second electrical connector is arranged on one of the engaging portions in correspondence with the first electrical connector.

Abstract: The present invention is to provide a monitoring system including a plurality of motion sensing carpets and a monitoring device (e.g., a computer) electrically connected to one of the motion sensing carpets serving as a control unit while all the other motion sensing carpets directly or indirectly joined to the control unit serves as auxiliary units. The monitoring device is able to carry out a topology algorithm and then establish a topology matrix of the motion sensing carpets in a stepwise manner so as to obtain the relative location of each motion sensing carpet. When any of the motion sensing carpets is subjected to pressure caused by a senior member or child in the family toppling over thereon (e.g., an accident) and generates a sensing signal, the monitoring device can rapidly know from the topology matrix the exact location of the accident according to the sensing signal.